Skip to main content

IP Update: Jun 4, 2009

Premium

Title: siRNA Targeting Aquaporin 4

Number: 7,541,453

Filed: Nov. 9, 2006

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed."


Title: Interfering RNAs Targeting the Morbillivirus Nucleoprotein Gene

Number: 20090136544

Filed: Dec. 12, 2006 PCT Filed: Dec. 12, 2006

Lead Inventor: Emmanuel Albina, French Agricultural Research Centre for International Development

"The invention relates to interfering RNAs … directed against conserved regions of the mRNA of the N gene encoding the morbillivirus nucleoprotein," the patent application's abstract states. "The invention also relates to the use of said interfering RNAs for the production of medicaments for use in the treatment or prevention of a morbillivirus infection."


Title: Targeting Opposite Strand-Replication Intermediates of Single-Stranded Viruses by RNAi

Number: 20090137039

Filed: Aug. 29, 2008

Lead Inventor: Daniel McCallus, Nucleonics

"The invention relates to methods and compositions for modulating viral replication through double-stranded RNA-mediated gene silencing, wherein the antiviral methods and compositions preferentially target opposite strand-replication intermediates of single-stranded RNA viruses," the patent application's abstract states.


Title: Splicing-Mediated Regulation of Gene Expression

Number: 20090137046

Filed: Oct. 31, 2007

Lead Inventor: Andrea Calixto, Columbia University

The invention, the patent application's abstract states, "relates to methods and compositions for controlling the expression of a target gene, whereby an intron cassette such as INT9, an intronic mec-2-derived element, is incorporated into the target gene and expression of the product of the target gene is conditional upon functional expression of the RNA processing protein, mec-8."

[ pagebreak ]

Title: RNA Interference-Mediated Inhibition of Gene Expression Using Chemically Modified Short Interfering Nucleic Acid

Number: 20090137500

Filed: Nov. 24, 2003

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

The invention, the patent application's abstract states, "concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target-validation, and genomic-discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid … capable of mediating RNA interference against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism."


Title: microRNA Target Site-Blocking Oligos and Uses Thereof

Number: 20090137504

Filed: Dec. 21, 2007

Lead Inventor: Soren Morgenthaler Echwald, Exiqon

The invention relates to "nucleic acids designed to prevent the binding of endogenous or exogenous microRNA and diagnostic and therapeutic uses thereof," the patent application's abstract states.


Title: Method for Predicting and Identifying Target mRNAs Controlled by Functional RNAs and Methods of Using the Same

Number: 20090137505

Filed: Sept. 20, 2006 PCT Filed: Sept. 20, 2006

Lead Inventor: Roberto Antonio Barrero, Center for Information Biology and DNA Data Bank of Japan

The patent application, its abstract states, claims "a method of predicting or identifying miRNAs and one or more target mRNAs targeted thereby [by] calculating the most stable secondary structures of double-stranded RNAs, which can be formed by all partial sequences in all of the subject mRNAs with miRNAs, and the secondary structure energies thereof to thereby search for all partial sequences capable of having stable structures through the binding of miRNAs to mRNAs."

The next step in the process involves calculating the "most stable secondary structure, which can be formed by a subject partial sequence or regions in the vicinity of the subject partial sequence with partial sequences of the concerned mRNA, and the secondary structure energy thereof to thereby determine whether or not the subject partial sequence of the concerned mRNA has a structure capable of interacting with the miRNA," the abstract notes.

[ pagebreak ]

Title: RNA Interference-Mediated Inhibition of Cyclic Nucleotide Type 4 Phosphodiesterase Gene Expression Using Short Interfering Nucleic Acid

Number: 20090137506

Filed: May 2, 2008

Lead Inventor: Walter Strapps, Sirna Therapeutics (Merck)

"The invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases, and conditions that respond to the modulation of cyclic nucleotide type 4 phosphodiesterase gene expression and/or activity, including PDE4B1, PDE4B2, and PDE4B3," the patent application's abstract states.

"The invention relates to double-stranded nucleic acid … capable of mediating RNA interference against cyclic nucleotide type 4 phosphodiesterase gene expression, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such small nucleic acid molecules. Such small nucleic acid molecules are useful, for example, in providing compositions to prevent, inhibit, or reduce inflammatory, respiratory, and autoimmune diseases, traits, and conditions, and/or other disease states associated with PDE4B gene expression or activity in a subject or organism," it adds.


Title: RNA Interference-Mediated Inhibition of Angiopoietin Gene Expression Using Short Interfering Nucleic Acid

Number:
20090137507

Filed: July 2, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating angiopoietin gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of angiopoietin gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of angiopoietin genes, such as angiopoietin-1, angiopoietin-2, angiopoietin-3, and angiopoietin-4."


Title: RNA Interference-Mediated Inhibition of Polycomb Group Protein EZH2 Gene Expression Using Short Interfering Nucleic Acid

Number:
20090137508

Filed:
July 2, 2008

Lead Inventor:
James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating polycomb group protein EZH2 gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of polycomb group protein EZH2 gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of polycomb group protein EZH2 genes, such as EZH2."

[ pagebreak ]

Title: RNA Interference-Mediated Inhibition of Proliferation Cell Nuclear Antigen Gene Expression Using Short Interfering Nucleic Acid

Number: 20090137509

Filed: July 2, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating PCNA gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of PCNA gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of PCNA genes. The small nucleic acid molecules are useful in the treatment of cancer or restenosis or other proliferative diseases, disorders, or conditions."


Title: RNA Interference-Mediated Inhibition of NF-Kappa B/REL-A Gene Expression Using Short Interfering Nucleic Acid

Number: 20090137510

Filed: July 10, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating NF-kappa B, REL-A, REL-B, REL, NK-kappa B1, or NF-kappa B2 gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NF-kappa B, REL-A, REL-B, REL, NK-kappa B1, or NF-kappa B2 gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of NF-kappa B, REL-A, REL-B, REL, NK-kappa B1, or NF-kappa B2 genes, such as NF-kappa B and/or REL-A."


Title: RNA Interference-Mediated Inhibition of Placental Growth Factor Gene Expression Using Short Interfering Nucleic Acid

Number: 20090137511

Filed: July 10, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating placental growth factor gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of placental growth factor gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of placental growth factor genes."

[ pagebreak ]

Title: RNA Interference-Mediated Inhibition of Cyclin D1 Gene Expression Using Short Interfering Nucleic Acid

Number: 20090137512

Filed: Aug. 28, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating cyclin and/or cyclin-dependent kinase gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of cyclin and/or cyclin-dependent kinase gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of cyclin and/or cyclin-dependent kinase genes."


Title: RNA Interference-Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid

Number: 20090137513

Filed:
Aug. 28, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating acetyl-CoA carboxylase gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of acetyl-CoA carboxylase gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of acetyl-CoA carboxylase genes."

[ pagebreak ]

Title: Compositions and Methods of Treating Dyslipidemia

Number: 20090137516

Filed:
Nov. 3, 2008

Lead Inventor: Helen Bayes Hartman, Wyeth

"The invention relates to the treatment of subjects for the purpose of reducing serum LDL, VLDL, triglycerides, and fatty acids by administering agents which reduce the activity of the bile acid pathway component SHP," the patent application's abstract states. "Methods and pharmaceutical preparations comprising such agents are provided."

Specifically claimed in the application are siRNAs and shRNAs capable of inhibiting SHP.


Title: Sensitizing a Cell to Cancer Treatment by Modulating the Activity of a Nucleic Acid Encoding RPS27L Protein

Number: 20090137517

Filed: March 1, 2007 PCT Filed: March 1, 2007

Inventor: Qiang Yu, Singapore's Agency for Science, Technology, and Research

The invention, the patent application's abstract states, "refers to a method of sensitizing a cell to cancer treatment comprising modulating the activity of a nucleic acid which encodes the RPS27L protein by use of … an RNAi agent or an antisense nucleotide molecule. The oligonucleotides of the … invention can be used in combination with at least one cytostatic drug for, e.g., chemotherapy."

The abstract adds that the invention "further refers to an expression vector comprising an oligonucleotide used in the method of the … invention as well as to a pharmaceutical comprising the oligonucleotides together with at least one chemotherapeutic agent."

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.